Antiaging Atlanta

Antiaging Atlanta - Hormone Replacement Therapy, Dr. Smith former Cenegenics MD

Contact: 678-566-3602 / rsmith@antiagingatlanta.com / email or call me for your initial assessment at no cost

12600 Deerfield Pkwy, STE 100, Alpharetta, GA 30004 (Atlanta, GA)

822 A1A North, Ponte Vedra Beach, FL 32082 (Jacksonville, FL) - coming soon

Cenegenics

Antiaging Medicine

Antiaging Medicine is preventive medicine focused on regaining and maintaining optimal health and quality of life as well as preventing chronic diseases of aging.

Check your hormone deficiency symptoms:

Aging Male Symptoms Checklist for TRT Testosterone Hormone Replacement Therapy

Menopause Symptoms Checklist for HRT Hormone Replacement Therapy

Antiaging Atlanta (Alpharetta)

Dr. Randy Smith, former President of Cenegenics Atlanta (Alpharetta) Georgia, offers an antiaging medicine program including hormone replacement therapy in the Atlanta (Alpharetta) Georgia area to improve women and men's health and quality of life.

While most Antiaging Atlanta clients are in the greater metro Atlanta area, Dr. Smith also treats men and women from surrounding states and other parts of the country as well.

Hormone Replacement Therapy is one of the foundations of an Antiaging Atlanta health program. Hormone Replacement Therapy may include Testosterone Replacement Therapy or TRT, DHEA, HGH, or Sermorelin which stimulates HGH production, for men and women as determined by clinical and laboratory testing. HGH requires more extensive evaluation and stimulation testing prior to use.

Estradiol and Progesterone hormone replacement therapy may be prescribed for menopausal or peri-menopausal women based on a health risk-benefit assessment.

In addition to hormone replacement therapy, HCG may be used in men to stimulate testosterone production, or in men or women as part of a weight loss program. Hormone replacement therapy with pregnenolone, cortisol, thyroid and other hormones may play a role as well.

Sermorelin acetate has become increasingly popular as a less expensive but effective alternative to human growth hormone replacement therapy. Sermorelin works by mimicking the effects of growth hormone releasing hormone on the pituitary gland.

There are also new GHRH peptides available that are more effective than sermorelin as GHRH, such as CJC 1295 and ipamorelin, CJC 1295 may also be combined with ipamorelin which works on the ghrelin receptor for a synergistic benefit in HGH and IGF1 production.

Best results are achieved through combining multiple Anti Aging Medicine program elements including Bio Identical Hormone Replacement Therapy, Nutritional Supplementation, Low Glycemic Index Nutrition, Strength Training and Aerobic Exercise, and Stress Reduction.

More detailed disease prevention strategies can be developed through human genome testing by 23andme.com and genomic based medical reports generated by promethease.com, and genomic based supplement recommendations generated by Puregenomics.

Peptide Bioregulation

Peptide Bioregulation is an antiaging treatment that acts at the genetic level.  It was developed over the last 30 years, by Dr. Vladimir Khavinson, head of the St. Petersburg Institute of Bioregulation and Gerontology in Russia at the request of the Government to reverse premature aging due to radiation exposure.

Antiaging Atlanta therapies can be categorized as:

While optimal benefits are achieved utilizing all components, many benefits are obtained by hormone optimization alone. There is no set program for everyone - each client is treated as the unique individual they are, and a program is designed specifically for each person.

Also ask about:

Telomere Testing by Life Length, Human Genome Testing by 23andme, Promethease Disease Risk Report, PureGenomics, and Cleveland Heart Lab and OmegaCheck

Email Dr. Randy Smith, AntiAging Atlanta (Alpharetta), former President of Cenegenics Atlanta (Alpharetta), Georgia to schedule a consultation.

Cenegenics Affiliate Atlanta  
 
12600 Deerfield Parkway
 
Alpharetta, GA 30004
 
office 678-566-3602
       
 
 
       

How am I different than the other Antiaging programs?

_____________________________________________________________________________________________________

Antiaging Atlanta - is it right for you?

Do You Need Hormone Replacement Therapy and improvements in:

I am Dr. Randy Smith, President, AntiAging Atlanta, and I am here to help you.

Antiaging Atlanta is a medical practice focused on improving your quality of life and overall health.

I started AntiAging Atlanta in 2004 shortly after I overcame some of my own health challenges utilizing the components of my program, which included hormone replacement therapy, nutritional supplementation, exercise, and a low carbohydrate diet.

As you can see from the photos I had some work to do. I figured if I could do it, I could help others as well. http://www.antiagingatlanta.com/beforeandafterrvs.htm This program allowed me a second chance at life.

From 2007 until the end of 2013 I was President of Cenegenics Atlanta, however the company as a whole got too large and commercialized for me, and the program evolved into something too complex and expensive.

In early 2014 I elected to return to a solo practice style where I can give truly individualized treatment to my patients at a more affordable price.

The Aging Process

The Program

You will be provided an effective, time efficient, and reasonably priced AntiAging Medicine program comprised of following main components:

By adjusting key hormone levels to the youthful end of the spectrum and providing optimal levels of nutrients through supplementation, your body becomes energized and highly responsive to even minor changes in life style such as exercise and diet.

How the Program Works:

Ready to start?

Email me today at rsmith@antiagingatlanta.com

I look forward to working with you and getting you on the path to optimum health and quality of life.

_______________________________________________________________________________________________________

Dr. Smith, former President of Cenegenics Atlanta (Alpharetta), feels the most successful antiaging medicine programs for men and women integrate the five elements of HRT, or hormone replacement therapy, using bio-identical hormones for deficient adults including HGH or Human Growth Hormone, Sermorelin, Testosterone, DHEA, and potentially Estradiol & Progesterone in women, a balanced low glycemic index diet, scientifically based prescription dietary supplements or nutraceuticals, aerobic and resistance exercise, and stress reduction. The synergy of these antiaging medicine elements promotes optimal health, energy, and vitality, a lean body composition and ideal body weight, thereby improving women and men's health.

The use of hormone replacement therapy including Sermorelin and Human Growth Hormone or HGH, GHRH peptides, Testosterone, DHEA, Estradiol and Progesterone is limited to adult men and women with clinical indications, and hormonal deficiencies documented by laboratory testing.

Dr. Randy Smith - Treatment Philosophy

Dr. Randy Smith, former President of Cenegenics Atlanta (Alpharetta), is passionate about helping people optimize their health and increase their vitality. Disease prevention and enhancement of quality of life are the goals of our comprehensive antiaging program. In addition most patients report significant improvements in muscle tone, achieve a more youthful body composition, and experience improved sexual functioning and increased energy and stamina.

During your Age Management Medicine assessment Doctor Smith, former President of Cenegenics Atlanta (Alpharetta), will design a customized program incorporating the essential elements of hormonal optimization, nutritional supplementation, dietary modification, exercise, and stress reduction specifically for you to meet your health and wellness goals.

Email Dr. Smith today about starting your personal Antiaging Medicine program. Dr. Smith, former President of Cenegenics Atlanta (Alpharetta), will provide a complimentary consultation either in person or by phone for prospective clients.

 

HGH Human Growth Hormone Abstracts

  1. Adolescents with partial human growth hormone HGH deficiency develop alterations of body composition after HGH discontinuation and require follow-up.
  2. Adults with partial human growth hormone HGH deficiency have an adverse body composition.
  3. Antipituitary antibodies in adults with apparently idiopathic HGH human growth hormone deficiency and in adults with autoimmune endocrine diseases.
  4. Baseline characteristics and response to 2 years of growth hormone HGH replacement of hypopituitary patients with HGH deficiency due to adult onset craniopharyngioma in comparison with patients with nonfunctioning pituitary adenoma: data from KIMS\
  5. Body mass index determines evoked human growth hormone HGH responsiveness in normal healthy male subjects: diagnostic caveat for adult HGH deficiency.
  6. Cardiac dimension and function in patients with childhood onset human growth hormone HGH deficiency, before and after human growth hormone retreatment in adult age.
  7. Comparison of continuation or cessation of growth hormone HGH therapy on body composition and metabolic status in adolescents with severe HGH deficiency at completion of linear growth.
  8. Cortical bone density is normal in prepubertal children with human growth hormone HGH deficiency, but initially decreases during HGH replacement due to early bone remodeling.
  9. Decreased quality of life in adult patients with HGH human growth hormone deficiency compared with general populations using the new validated, self weighted questionnaire, questions on life satisfaction hypopituitarism module.
  10. Do all patients with childhood onset growth hormone deficiency HGHD and ectopic neurohypophysis have persistent HGHD in adulthood?
  11. Does a gender related effect of growth hormone HGH replacement exist on cardiovascular risk factors cardiac morphology and performance and atherosclerosis? Results of a two-year open prospective study in young adult men and women with severe GH deficiency.
  12. Effect of human growth hormone HGH and/or testosterone replacement on the prostate in HGH-deficient adult patients.
  13. Effect of human growth hormone HGH treatment on bone in postpubertal HGH-deficient patients: a 2-year randomized, controlled, dose-ranging study.
  14. Effect of recombinant human growth hormone HGH replacement on the hypothalamic pituitary-adrenal axis in adult HGH deficient patients.
  15. Effects of human growth hormone HGH on ghrelin, leptin, and adiponectin in HGH-deficient patients.
  16. Effects of human growth hormone HGH replacement therapy on low-density lipoprotein apolipoprotein B100 kinetics in adult patients with HGH deficiency: a stable isotope study.
  17. Efficacy and tolerability of an individualized dosing regimen for adult human growth hormone replacement therapy in comparison with fixed body weight-based dosing.
  18. Endothelial function and coagulant factors in human growth hormone HGH treated hypopituitary adults receiving desmopressin.
  19. Evaluation of diagnostic accuracy of insulin like growth factor IGF I and IGF binding protein 3 in growth hormone deficient children and adults using ROC plot analysis.
  20. Exercise training benefits human growth hormone HGH-deficient adults in the absence or presence of HGH treatment.
  21. Five years of human growth hormone HGH replacement therapy in adults: age- and gender-related changes in isometric and isokinetic muscle strength.
  22. Growth hormone deficiency predicts cardiovascular risk in young adults treated for acute lymphoblastic leukemia in childhood.
  23. High risk of adrenal insufficiency in adults previously treated for idiopathic childhood onset human growth hormone HGH deficiency.
  24. Human Growth hormone HGH dose-response in young adults with childhood-onset GH deficiency: a two-year, multicenter, multiple-dose, placebo-controlled study.
  25. Human growth hormone HGH replacement is important for the restoration of parathyroid hormone sensitivity and improvement in bone metabolism in older adult human growth hormone-deficient patients.
  26. Human Growth hormone HGH replacement therapy in adult-onset hgh deficiency: effects on body composition in men and women in a double-blind, randomized, placebo-controlled trial.
  27. Human growth hormone increases vascular cell adhesion molecule 1 expression: in vivo and in vitro evidence.
  28. Impact of human growth hormone HGH treatment on cardiovascular risk factors in HGH-deficient adults: a Metaanalysis of Blinded, Randomized, Placebo-Controlled Trials.
  29. Induction of postprandial inflammatory response in adult onset human growth hormone HGH deficiency is related to plasma remnant-like particle-cholesterol concentration.
  30. Limited efficacy of human growth hormone HGH during transition of HGH deficient patients from adolescence to adulthood: a phase III multicenter, double-blind, randomized two-year trial.
  31. Long term HGH human growth hormone therapy in adulthood results in significant linear growth in siblings with a PROP 1 gene mutation.
  32. Long term improvement of quality of life during human growth hormone HGH replacement therapy in adults with HGH deficiency, as measured by questions on life satisfaction-hypopituitarism (QLS-H).
  33. Low bone mass is an infrequent feature of the adult human growth hormone HGH deficiency syndrome in middle-age adults and the elderly.
  34. Metabolic effects of 20 kilodalton human growth hormone (20K-hGH) for adults with growth hormone deficiency: results of an exploratory uncontrolled multicenter clinical trial of 20K-hGH.
  35. Quality of life in childhood onset HGH human growth hormone-deficient patients in the transition phase from childhood to adulthood.
  36. Rational use of the laboratory for childhood and adult HGH human growth hormone deficiency.
  37. Reduced longevity in untreated patients with isolated HGH human growth hormone deficiency.
  38. Seeking the optimal target range for insulin-like growth factor I during the treatment of adult human growth hormone HGH disorders.
  39. Short- and long-term effects of human growth hormone HGH replacement on protein metabolism in HGH-deficient adults.
  40. Short term effects of human growth hormone HGH treatment or deprivation on cardiovascular risk parameters and intima media thickness at carotid arteries in patients with severe HGH deficiency.
  41. The characteristics of quality of life impairment in adult growth hormone HGH deficient survivors of cancer and their response to HGH replacement therapy.
  42. The effect of cessation of human growth hormone HGH therapy on bone mineral accretion in HGH deficient adolescents at the completion of linear growth.
  43. The Impact of congenital, severe, untreated human growth hormone HGH deficiency on bone size and density in young adults: insights from genetic HGH-releasing hormone receptor deficiency.
  44. The mathematical model for total pubertal growth in idiopathic human growth hormone HGH deficiency suggests a moderate role of HGH dose.
  45. The usefulness of the combined human growth hormone HGH -releasing hormone and arginine stimulation test in the diagnosis of radiation-induced HGH deficiency is dependent on the post-irradiation time interval.
  46. Bone status and fracture prevalence in Russian adults with childhood-onset human growth hormone HGH deficiency.
  47. Clinical review: Human Growth hormone HGH and cardiovascular risk factors.
  48. Effect of human growth hormone HGH on glycerol and free fatty acid metabolism during exhaustive exercise in GH-deficient adults.
  49. Human growth hormone HGH replacement therapy induces insulin resistance by activating the glucose-fatty acid cycle.
  50. Malignant disease and cardiovascular morbidity in hypopituitary adults with or without human growth hormone HGH replacement therapy.
  51. Common carotid intima-media thickness in human growth hormone HGH-deficient adolescents: a prospective study after HGH withdrawal and restarting HGH replacement.
  52. Diagnostic and therapeutic advances in human growth hormone HGH insensitivity.
  53. Endothelial function, carotid artery intima-media thickness, epicardial adipose tissue, and left ventricular mass and function in growth hormone-deficient adolescents: apparent effects of human growth hormone HGH treatment on these parameters.
  54. Influence of body mass index and gender on human growth hormone HGH responses to HGH-releasing hormone plus arginine and insulin tolerance tests.
  55. Peripheral inflammatory and fibrinolytic markers in adolescents with human growth hormone deficiency HGH-D: relation to postprandial dyslipidemia.
  56. Treatment of cachexia with HGH releasing peptide ghrelin in patients with COPD.
  57. Human Growth hormone releasing peptide-2 (HGHRP-2), like ghrelin, increases food intake in healthy men.
  58. Peripheral inflammatory and fibrinolytic markers in adolescents with human growth hormone deficiency HGH-D: relation to postprandial dyslipidemia.
  59. Short-term administration of supraphysiological recombinant human growth hormone HGH does not increase maximum endurance exercise capacity in healthy, active young men and women with normal HGH-insulin-like growth factor I axes.
  60. Platelet hyperactivation in maintained human growth hormone HGH-deficient childhood patients after therapy withdrawal as a putative earlier marker of increased cardiovascular risk.

Testosterone Hormone Replacement Therapy Abstracts

  1. The effect of testosterone replacement on endogenous inflammatory cytokines and lipid profiles in hypogonadal men.
  2. Testosterone treatment enhances regional brain perfusion in hypogonadal men.
  3. Effects of testosterone replacement in human immunodeficiency virus-infected women with weight loss.
  4. Andropause: an old concept in new clothing.
  5. A comparison of a novel testosterone bioadhesive buccal system, striant, with a testosterone adhesive patch in hypogonadal males.
  6. Effects of aromatase inhibition in elderly men with low or borderline-low serum testosterone levels.
  7. Testosterone replacement therapy restores normal ghrelin in hypogonadal men.
  8. Erectile dysfunction: etiology and treatment in young and old patients.
  9. Female sexual dysfunction in postmenopausal women: systematic review of placebo-controlled trials.
  10. AA2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function.
  11. Male hypogonadism in the primary care clinic.
  12. Testosterone dose-dependently increases maximal voluntary strength and leg power, but does not affect fatigability or specific tension.
  13. Independent and combined effects of testosterone and growth hormone on extracellular water in hypopituitary men.
  14. Effects of dehydroepiandrostenedione, superimposed on growth hormone substitution, on quality of life and insulin-like growth factor I in patients with secondary adrenal insufficiency: a randomized, placebo-controlled, cross-over trial.
  15. Dose-dependent effects of testosterone on sexual function, mood, and visuospatial cognition in older men.
  16. Gonadal and erectile dysfunction in diabetics.
  17. Prevention and treatment of erectile dysfunction using lifestyle changes and dietary supplements: what works and what is worthless, part II.
  18. Current controversies in testosterone testing: aging and obesity.
  19. Dose-dependent effects of testosterone on regional adipose tissue distribution in healthy young men.
  20. Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone.
  21. Increased risk of falls and increased bone resorption in elderly men with partial androgen deficiency: the MINOS study.
  22. Endocrine causes of impotence (nondiabetes).
  23. Testosterone and behavior.
  24. Testosterone improves spatial memory in men with Alzheimer disease and mild cognitive impairment.
  25. Effects of androgen therapy on adipose tissue and metabolism in older men.
  26. Blood testosterone threshold for androgen deficiency symptoms.
  27. Current controversies in testosterone testing: aging and obesity.
  28. Prevalence and incidence of androgen deficiency in middle-aged and older men: estimates from the Massachusetts Male Aging Study.
  29. Testosterone and depression in men aged over 50 years. Andropause and psychopathology: minimal systemic work-up.
  30. Androgens, andropause and neurodegeneration: exploring the link between steroidogenesis, androgens and Alzheimer's disease.
  31. Sex hormones and coronary artery disease.
  32. Lower endogenous androgens predict central adiposity in men.
  33. Effects of testosterone supplementation in the aging male.
  34. Longitudinal relation between endogenous testosterone and cardiovascular disease risk factors in middle-aged men. A 13-year follow-up of former Multiple Risk Factor Intervention Trial participants.
  35. Therapeutic effects of an androgenic preparation on myocardial ischemia and cardiac function in 62 elderly male coronary heart disease patients.
  36. Men with coronary artery disease have lower levels of androgens than men with normal coronary angiograms.
  37. Low-dose transdermal testosterone therapy improves angina threshold in men with chronic stable angina: A randomized, double-blind, placebo-controlled study.
  38. Testosterone as a protective factor against atherosclerosis--immunomodulation and influence upon plaque development and stability.
  39. Effects of testosterone administration on fat distribution, insulin sensitivity, and atherosclerosis progression.
  40. Effect of acute testosterone on myocardial ischemia in men with coronary artery disease.
  41. Testosterone and atherosclerosis.
  42. The association of hypotestosteronemia with coronary artery disease in men.
  43. Sex hormone concentrations in men with angiographically assessed coronary artery disease--relationship to obesity and body fat distribution.
  44. Plasma levels of estradiol, testosterone, and DHEAS do not predict risk of coronary artery disease in men.
  45. Abnormalities in sex hormones are a risk factor for premature manifestation of coronary artery disease in South African Indian men.
  46. Sex hormones in men with coronary arteriosclerosis.
  47. Sex hormones and coronary artery disease.
  48. Usefulness of sex steroid hormone levels in predicting coronary artery disease in men.
  49. Sex hormone levels in young Indian patients with myocardial infarction.

 

| Site Map | Links & Resources | Contact Us | 2004 - 2017 Anti-Aging & Weight Loss Medicine, LLC

041915